GlaxoSmithKline

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, GlaxoSmithKline sits in the top decile of US sponsors by registered trial count (#17 of 15,742 sponsors by registered trial count).

1,345 total trials 50 currently recruiting 1130 completed early-phase tilt top decile by trial count

GlaxoSmithKline: 1,345 sponsored US clinical trials, 50 recruiting.

GlaxoSmithKline sponsors 1,345 registered US clinical trials on ClinicalTrials.gov, 50 of them currently recruiting, and 1,130 completed. 486 of these trials are in Phase 3-4 (later-stage) and 791 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pulmonary Disease, Chronic Obstructive, with 30 trials.

Top-decile sponsor footprint

GlaxoSmithKline ranks in the top decile of sponsors by registered trial count (#17 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 66/100

1,130 of 1,249 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,345 total, page 26 of 27

COMPLETED Phase 2

A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary Insomnia

NCT00650871

COMPLETED Phase 3

A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)

NCT00094367

COMPLETED Phase 2

Study Of Ispinesib In Subjects With Breast Cancer

NCT00089973

COMPLETED Phase 1

Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

NCT00359190

COMPLETED Phase 4

A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.

NCT00158860

COMPLETED Phase 2

Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer

NCT00089999

COMPLETED Phase 2

Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease

NCT00265148

COMPLETED Phase 3

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

NCT00122681

COMPLETED Phase 3

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

NCT00085943

COMPLETED Phase 3

Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia

NCT00086593

COMPLETED Phase 4

Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.

NCT00355342

COMPLETED Phase 4

A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV

NCT00082394

COMPLETED Phase 3

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

NCT00224484

COMPLETED Phase 1

SB-743921 In Patients With Solid Tumors

NCT00136513

COMPLETED Phase 1

Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas

NCT00085904

COMPLETED Phase 1

Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected Adults

NCT00090077

COMPLETED Phase 3

Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)

NCT00086658

TERMINATED Phase 4

A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons

NCT00079911

COMPLETED Phase 3

An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease

NCT00632736

COMPLETED

Effects Of Prednisolone On Rheumatoid Arthritis Patients

NCT00330889

COMPLETED Phase 3

Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer

NCT00075270

COMPLETED Phase 1

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults

NCT00730795

COMPLETED Phase 4

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

NCT00118716

COMPLETED Phase 2

Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer

NCT00085813

COMPLETED Phase 3

Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine

NCT00224471

COMPLETED Phase 3

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

NCT00363727

COMPLETED Phase 4

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

NCT00118690

COMPLETED Phase 3

Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

NCT00197236

COMPLETED Phase 3

Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment

NCT00090103

COMPLETED Phase 3

Depression And Bipolar Disorder

NCT00274677

COMPLETED Phase 2

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

NCT00169559

COMPLETED Phase 2

Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults

NCT00120848

TERMINATED Phase 2

A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer

NCT00073008

COMPLETED Phase 3

A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics

NCT00067951

COMPLETED Phase 3

Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects

NCT00499707

COMPLETED Phase 3

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

NCT00197015

COMPLETED Phase 4

Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels

NCT00062790

COMPLETED Phase 1

Seasonal Affective Depression (SAD) Study

NCT00069459

COMPLETED Phase 3

Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age

NCT00197002

COMPLETED Phase 2

Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer

NCT00065182

COMPLETED Phase 3

A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome

NCT00363857

COMPLETED Phase 3

Clinical Study Of Schizophrenia in Both Men and Women

NCT00071747

COMPLETED Phase 4

Bipolar Study in Adults at Least 18 Years of Age

NCT00067938

COMPLETED Phase 3

Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

NCT00067561

COMPLETED Phase 3

Lethargic Depression Study

NCT00064467

COMPLETED Phase 3

Depression Study In Elderly Patients

NCT00067444

COMPLETED Phase 3

Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

NCT00067457

COMPLETED Phase 3

Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa

NCT00381472

COMPLETED Phase 1

Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)

NCT00148902

COMPLETED Phase 1

Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab

NCT00062894

← Previous Page 26 of 27 Next →

Phase Distribution

PhaseTrial count
Phase 1 440
Phase 2 351
Phase 3 377
Phase 4 109

What is open in the GlaxoSmithKline pipeline

50 recruiting of 1,345 indexed (4% open); 1,130 completed (84%).

Phase mix: 486 late (III/IV) vs 791 early (I/II) (early-phase heavy).

Top condition: Pulmonary Disease, Chronic Obstructive (30 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

GlaxoSmithKline: open-pipeline peers nationwide

Peers matched on 1,345 registered trials and 4% open enrollment, not the therapeutic-area sidebar.

GlaxoSmithKline sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 0%5%10%15% Total trials Recruiting share GlaxoSmithKlineEli Lilly and CompanyUniversity of MichiganNovartis PharmaceuticalsAstraZenecaStryker OrthopaedicsUS Oncology ResearchOtsuka Pharmaceutical Development & CommercializationTeva Branded Pharmaceutical Products R&D
GlaxoSmithKline sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

GlaxoSmithKline sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,345 trials (± recruiting share)

Sponsors near 4% open enrollment (± trial volume)

What to do with this GlaxoSmithKline page

1,345 registered trials is a research-attention snapshot, not an endorsement of GlaxoSmithKline or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. GlaxoSmithKline pipeline card: 1,345 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.